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Abstract
Glivec is a relatively small molecule with activity against the protein tyrosine kinase, a protein expressed by all
patients with chronic myelogenous leukemia (CML). Based on its activity on CML, glivec is undergoing extensive
evaluation of its activity against other types of tumor. As a result, there is an ongoing need for clarification of glivec
pharmacokinetics so that issues such as drug-biomolecular complex interactions can be understood.
The interaction of DNA with the antileukemia drug glivec was investigated in bulk solution and at a dsDNA-
electrochemical biosensor using differential pulse voltammetry. It was found that glivec binds to dsDNA and this
interaction leads to modifications in the dsDNA structure, electrochemically recognized through changes of the
anodic oxidation peaks of guanosine and adenosine bases. The dsDNA-biosensor enabled the in situ electrochemical
generation of glivec redox metabolites and the detection of DNA oxidative damage. Using polynucleotides of known
sequence it has been proved that the interaction between glivec and DNA takes place at adenine enriched segments.
The generation of glivec oxidation product inside the DNA double helix leads to oxidation of adenine residues and
the electrochemical detection of 2,8-dihydroxyadenine. An interaction mechanism is proposed and the formation of
2,8-dihydroxyadenine is explained.
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1. Introduction
Chronic myeloid leukemia (CML) is a malignancy charac-
terized by an elevated number of white blood cells.
Cytogenetic studies performed decades ago [1, 2] correlated
the disease with the presence of the abnormal Philadelphia
chromosome [3, 4]. The consequence is the creation of a
BCR-ABL fusion protein, a constitutively active cytoplas-
mic protein-tyrosine kinase [5 – 6].
CML, at least in the stable phase, is unique among
malignancies in that the malady appears to be the result of a
single major biochemical defect, the BCR-ABL protein. In
contrast, most malignancies are the result of several genetic
and biochemical lesions [7 – 8]. Additional mutations ac-
count for CML progression from a stable phase to the
accelerated and blast phases. The BCR-ABL oncoprotein
thus represents a unique drug target. Purification of the
BCR-ABL protein and X-ray crystallography of the tyro-
sine kinase domain led to the design of a small molecule that
could bind and block the phosphorylation of kinase activity
[9 – 10].
Glivec (Gleevec, STI 571 or imatinib mesylate),
Scheme 1, a derivative of 2-phenylaminopyrimidine, is
believed to competitively inhibit the binding of ATP by
interacting with the ATP-binding site of tyrosine kinases
[11]. This inhibits the ability of ABL to transfer phosphate
groups from ATP and phosphorylate tyrosine residues on
substrate proteins, which in turn prevents the transduction
of energy signals necessary for ABL-induced cellular
proliferation and apoptosis. Thus, the specific signal trans-
duction pathway abnormally activated in the leukemic
transformation process is inactivated by glivec while the
normal pathways are unaffected. Clinical trials demonstrat-
ed the ability of glivec to induce hematologic and cytoge-
Scheme 1. Glivec chemical structure.
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netic remissions in patients in chronic phase as well as in
accelerated phase of CML.
Being a relatively new drug, there are only few references
about glivec in the specialized literature and most deal with
the analytical determination of glivec and its main meta-
bolite in urine or human plasma and are based on liquid
chromatography tandem mass spectrometry and electro-
phoretic methods [12 – 17].
Recently, using an alkaline comet assay, it was shown that
glivec at concentrations ranging from 0.2 to 2 mM induces
DNAdamage in human leukemic cells expressing theBCR-
ABL protein [18]. Also, it was demonstrated that glivec did
not induce DNA strand breaks in the direct interaction with
DNA but rather alkali-labile sites. Moreover, the pretreat-
ment of the BCR-ABL protein expressing cells with
vitamins A, C and E reduced the extent of DNA damage
evoked by glivec. It was shown that the mechanism of the
antileukemic action of glivec may involve not only the
inhibition of BCR-ABL, but also DNA damage in the cells
expressing this fusion protein.
Based on its activity on CML, glivec is undergoing
extensive evaluation for its activity against other tumor
types [19 – 21]. As a result of these evaluations there is an
ongoing need for estimation of glivec pharmacokinetics so
that issues such as drug-biomolecular complex interactions
can be evaluated.
In the past decade, there has been great interest in the
development ofDNAbased biosensors.An electrochemical
sensor for DNA damage consists of an electrode with DNA
immobilized on the surface. Interactions of surface-immo-
bilized DNA (either by electrostatic adsorption or by
evaporation) with the damaging agent are converted, via
changes in electrochemical properties of the DNA recog-
nition layer, into measurable electrical signals. Such a kind
of device has been successfully applied to study the
interaction of several substances with dsDNA and the
interpretation of the results contributed to the elucidationof
the mechanisms by which DNA is damaged by hazardous
compounds [22 – 25].
In this context, the aim of the present paper is concerned
with the electrochemical study of the in situ interaction of
glivec with dsDNA immobilized on a glassy carbon elec-
trode surface. Several situations were studied using a
dsDNA modified glassy carbon electrode i.e. the DNA-
electrochemical biosensor. The experimental results pre-
sented here give strong evidence that by controlling the
electrode potential it is possible to detect not only modifi-
cations to the dsDNA structure but also damage to purinic
bases that occurs during redox processes of glivec meta-
bolites, electrochemically generatedon thebiosensor surface.
2. Experimental
2.1. Reagents
Glivec capsules of 100 mg imatinib were obtained from
Novartis. Double stranded DNA (dsDNA), single stranded
DNA (ssDNA) and polyadenilic (poly[A]) and polyguanilic
(poly[G]) acids were obtained from Sigma and used without
further purification. Stock solutions of 100 mM glivec, and
60 mg mL1 dsDNA, ssDNA, poly[A] and poly[G] were
prepared in pH 4.5 0.1 M acetate buffer electrolyte. All
solutions were prepared using analytical grade reagents and
purified water from a Millipore Milli-Q system (conducti-
vity 0.1 mS cm1).
Microvolumes were measured using EP-10 and EP-100
PlusMotorizedMicroliter Pipettes (Rainin Instruments Co.
Inc., Woburn, USA). The pH measurements were carried
out with a GLP 21 Crison pH meter. All experiments were
done in pH 4.5, 0.1 M acetate buffer at room temperature
(25 1 8C).
2.2. Voltammetric Parameters and Electrochemical Cells
Voltammetric experiments were carried out using a mAuto-
lab running with GPES version 4.9 software, Eco-Chemie,
Utrecht, The Netherlands. The experimental conditions for
differential pulse voltammetry (DPV) were: pulse ampli-
tude 50 mV, pulse width 70 ms, scan rate 5 mV s1. An
equilibration time of 5 seconds was always allowed before
each DPV scan. All measurements were carried out using a
glassy carbon (GCE) (d¼ 1.5 mm) working electrode, a Pt
wire counter electrode, and a Ag/AgCl (3 M KCl) as
reference, in a 0.5 mL one-compartment electrochemical
cell.
2.3. GCE Pretreatment
The GCE was polished using diamond spray (particle size
1 mm) before every electrochemical experiment. After
polishing, the electrode was rinsed thoroughly with Milli-
Q water for 30 s; then it was sonicated for 1 minute in an
ultrasound bath and again rinsed with water. After this
mechanical treatment, the GCE was placed in pH 4.5 0.1 M
acetate buffer electrolyte and various DP voltammograms
were recorded until a steady state baseline voltammogram
was obtained. This procedure ensured very reproducible
experimental results.
2.4. DNA Biosensors Preparation and Incubation
Procedure
The dsDNA-biosensors were prepared by successively
covering the GCE (d¼ 1.5 mm) surface with three drops
of 5 mL each of 60 mg mL1 dsDNA solution. After placing
each drop on the electrode surface the biosensor was dried
under a constant flux of N2. The ssDNA, poly[A] and
poly[G]-modified GCE were prepared in the same way.
Incubation with glivec was always carried out by holding
the biosensor during 2minutes (unless stated otherwise) in a
solution containing 5 mM glivec in pH 4.5 0.1 M acetate
buffer. During this period of time the solution was
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continuously stirred. Then, the electrode was rinsed with
deionized water to ensure the removal of unbound mole-
cules and transferred to acetate buffer where transduction
was performed, always using DPV.
2.5. Adsorption of Glivec Oxidation Product at the GCE
Surface
A pretreated GCE was held for 2 minutes in a solution of
5 mM glivec in pH 4.5 0.1 M acetate buffer. Then, the
electrode was washed with deionized water in order to
remove the unbound glivec molecules and placed in an
electrochemical cell containing only the supporting electro-
lyte. A potential ofþ0.90 Vwas applied during 2minutes to
enable the oxidation of glivec molecules adsorbed at the
GCE surface.
2.6. Acquisition and Presentation of Voltammetric Data
All the voltammograms presented were background-
subtracted and baseline-corrected using the moving
average application with a step window of 5 mV included
in GPES version 4.9 software. This mathematical treat-
ment improves the visualization and identification of
peaks over the baseline without introducing any artifact,
although the peak intensity is in some cases reduced
(<10%) relative to that of the untreated curve. Never-
theless, this mathematical treatment of the original voltam-
mograms was used in the presentation of all experimental
voltammograms for a better and clearer identification of the
peaks.
3. Results and Discussion
3.1. Voltammetry of Glivec at a GCE
The electrochemical behavior of adsorbed glivec at the
GCE surface, was briefly revisited in order to make it easier
to identify the peaks occurring after glivec – dsDNA inter-
action.
The DP voltammogram obtained in pH 4.5 0.1 M acetate
buffer after free adsorption for 2 minutes in a solution of
5 mM glivec is shown in Figure 1A – full line. The oxidation
peak 1a of glivec occurs at E1pa¼þ0.87 Vand is followed by
another peak 2a at E2pa¼þ1.20 V.
In a further experiment, after adsorption of glivec, the
GCEwas conditioned atþ0.90 Vduring 2minutes in pH 4.5
0.1 M acetate buffer. This procedure enabled the oxidation
of the adsorbed glivec molecules on the GCE surface. The
DP voltammogram obtained in buffer, Figure 1A, dotted
line, shows a new peak 3a at E3pa¼þ0.32 V. This peak
corresponds to oxidation of the glivec oxidation product,
Pglivec, adsorbed on the electrode surface. At the same time,
the oxidation current of glivec peak 1a decreases due to the
compound consumption during the conditioning procedure.
Peak 2a maintains the same current as in the previous
experiment.
In a third experiment, Pglivec was adsorbed at the electrode
surface as described in Section 2.5. Then, a SW voltammo-
gram was recorded in pH 4.5 0.1 M acetate buffer (Fig. 1B).
The reversibility of the oxidation ofPglivec is demonstrated by
plotting the forward and backward components of the total
current, where the oxidation and the reduction currents are
equal, Figure 1B. The identical value of the potential of
peak 3a in the forward and on the backward current
components is an indication of the adsorption of glivec
oxidation product at the GCE surface [26]. Moreover, Pglivec
remains adsorbed at the GCE surface, and consecutive SW
voltammograms recorded in buffer always showed the same
current for peak 3a (not shown).
Concerning DNA oxidation, it has been shown in experi-
ments carried out in pH 7 0.1 M phosphate buffer and in
pH 4.5 0.1 Macetate buffer, that it occurs at lower potentials
at physiological pH, but in pH 4.5 0.1 M acetate buffer the
DNA oxidation peak currents are several times higher [27].
This leads to lower detection limits in the identification of
DNA oxidative damage and for this reason subsequent
experiments were all carried out in pH 4.5 0.1 M acetate
buffer.
3.2. Analysis of Incubated Solutions
Initial studies of the interaction between glivec and DNA
were carried out by incubating a solution of 60 mg mL1
dsDNA with 1 mM glivec in pH 4.5 0.1 M acetate buffer.
Then DP voltammograms were recorded after different
incubation periods. The GCE surface was always renewed
between consecutive measurements in order to avoid the
Fig. 1. A) DP voltammograms obtained with a GCE in pH 4.5
0.1 M acetate buffer after free adsorption in 5 mM glivec (—)
without and ( ··· · · · ) with application of þ0.90 V during 2 minutes.
B) SW voltammogram obtained in pH 4.5 0.1 M acetate buffer
after adsorption of Pglivec at the GCE surface (more details in
Sec. 2.5). It: total current, If: forward current and Ib. backward
current; f¼ 25 Hz, DEs¼ 1 mV thus neffective ¼ 25 mV s1.
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blocking of the electrochemically active surface by adsorp-
tion of the oxidation products of both DNA and glivec.
The DP voltammogram obtained immediately after the
addition of glivec to the solution of dsDNA, Figure 2, full
line, shows the glivec oxidation peak 1a and twomore anodic
peaks at Epa¼þ1.00 VandEpa¼þ1.26 V. These two peaks
correspond to oxidation of the purinic DNA bases, desoxy-
guanosine (dGuo) and desoxyadenosine (dAdo), respec-
tively [28]. For longer incubation periods, higher dGuo and
dAdo oxidation peaks were obtained. The increase of the
DNA oxidation peaks occurs in a time-dependent manner
and takes place during 2 hours of incubation (not shown).
After this period, both dGuo and dAdo peaks reach a
constant size.
The increase of dGuo and dAdo peaks is attributed to
conformational changes in the dsDNA structure. The
dsDNA structure makes access of the bases to the electrode
surface difficult, hindering their oxidation. As the double
helix unwinds, easier access of the bases to the surface leads
to higher voltammetric signals [23 – 25]. On the other hand,
small positive shifts of about 20 mV of the oxidation
potential of glivec are observed in Figure 2, also proving
that an interaction between glivec and DNA had occurred.
Although the electrochemical experiments carried out in
incubated solutions showed changes of the dGuo and dAdo
peaks after interaction of DNA with glivec, the type of
modifications occurring in the dsDNA structure needs to be
understood. During voltammetric detection in the incuba-
ted solution, dsDNA and glivec adsorbed strongly on the
GCE surface leading to blockage of the electrode surface.
The peaks obtained could be due to oxidation of glivec
molecules adsorbed on the GCE surface besides those
complexed with dsDNA.
3.3. In Situ Study of Glivec-DNA Interaction
For a better understanding of the interaction between glivec
and DNA, a dsDNA-multilayer electrochemical biosensor
has been used (see Sec. 2.4). The electrode surface was
characterized byMACModeAFMand the images revealed
a complete surface coverage [27]. Consequently, undesired
adsorption of glivec molecules on the electrode surface is
not possible. The biosensor response can only arise from the
interaction of the compound with dsDNA without any
contribution from the diffusion process. Moreover, the
DNA-biosensor will allow the electrochemical generation
of glivec intermediates (metabolites) and the investigation
of the interaction of glivec oxidation products with DNA.
The changes occurring to dsDNA during its interaction
with glivec were followed by DPV, using the dsDNA-
biosensor. The GCE modification procedure with multi-
layer dsDNA is described in Section 2.4.
The DNA-biosensor was incubated for 1 minute in 5 mM
glivec solution and then transferred to acetate buffer where
DPV was performed, Figure 3, full line. As expected, the
voltammogramobtained shows glivec oxidation peak 1a and
the peaks due to the oxidation of DNA bases. The experi-
ment was always repeated with a new biosensor, varying the
incubation time, to 2 and 3 minutes of incubation (dotted
and dashed line, respectively). Increasing the incubation
time in the glivec solution, the glivec oxidation peak 1a also
increases. The binding of glivec molecules lead to modifi-
cations of the dsDNA film and this is detected by the
occurrence of increasing peaks for dGuo and dAdo, with
incubation time. The changes taking place in the dsDNA
conformation depend on the quantity of glivec bound to the
immobilized DNA. This experiment also demonstrates that
it is possible to preconcentrate glivec into the dsDNA film
and, that even after interaction with DNA, glivec can still
undergo oxidation.
After incubation with glivec, the dsDNA film was
removed from the electrode surface and a DP voltammo-
gram was recorded in buffer (not shown). No glivec
Fig. 2. DP voltammograms obtained with a GCE in a solution of
60 mg mL1 dsDNA incubated with 1 mM glivec in pH 4.5 0.1 M
acetate buffer after: (—) 1, ( ·· · · · · ) 30, and (- - - -) 120 minutes of
incubation.
Fig. 3. DP voltammograms obtained with multilayer dsDNA
biosensors in pH 4.5 0.1 M acetate buffer after incubation for: (—)
1, ( ·· · · · · ) 2, and (- - - -) 3 minutes in 5 mM glivec.
1966 V. C. Diculescu et al.
Electroanalysis 18, 2006, No. 19-20, 1963 – 1970 www.electroanalysis.wiley-vch.de H 2006 WILEY-VCH Verlag GmbH&Co. KGaA, Weinheim
oxidationpeakwasobserved, provingonce again a complete
coverage of the electrode surface after the modification
procedure with dsDNA.
In another experiment, a new dsDNA-biosensor was held
for 2 minutes in a stirred 5 mM glivec solution. After this
period, the biosensor was rinsed with deionized water and
immersed into acetate bufferwhere a conditioning potential
of þ0.90 V was applied during 1 minute. At this potential,
the glivec molecules attached to the dsDNA film are
oxidized leading to the formation of Pglivec. Therefore, in
the DP voltammogram recorded, Figure 4, dashed line,
oxidation peak 1a of glivec occurred with a smaller current
when compared with the voltammogram obtained without
the application of þ0.90 V, Figure 4, full line. Also, the
peak 3a specific to Pglivec can be observed. Nevertheless, a
new small peak occurs at Epa¼þ0.45 V. It must be
remarked that glivec oxidation at the bare GCE surface
does not give rise to any peak at þ0.45 V, as already shown
in Section 3.1, Figure 1A, dotted line.Also, the conditioning
potential ofþ0.90 Vdoes not oxidize the immobilizedDNA
since the oxidation of guanine (the most easily oxidized
DNA base) in pH 4.5 solution occurs at a higher potential,
e.g., Epa¼þ1.01 V. Therefore, the peak at Epa¼þ0.45 V is
caused by the interaction between DNA and the products
formed during the oxidation of glivec. The appearance of
this peak indicates the occurrence of products of DNA
oxidative damage during the oxidation process of glivec.
The above experiment was repeated varying the time
during which the potential ofþ0.90 V was applied. The DP
voltammogram obtained after conditioning the dsDNA-
biosensor for 2minutes is shown inFigure 4, dotted line. The
glivec oxidation peak 1a shows a decrease with the condi-
tioning time, due to glivec consumption.On the contrary, the
Pglivec oxidation peak 3a and the peak atEpa¼þ0.45 V show
an increase with conditioning time.
For a better understanding of the results obtained, the
electrode surface was also covered with a film of ssDNA.
The modification procedure for the ssDNA-biosensor is
described in Section 2.4. The DP voltammogram obtained
after modification of the GCE surface with ssDNA, Fig-
ure 5, dashed line, shows the two peaks due to dGuo and
dAdo oxidation. Subsequently, this ssDNA-biosensor was
incubated with glivec: the voltammogram recorded, Fig-
ure 5, dotted line, shows the glivec oxidation peak 1a. Also,
the small increase of dGuo and dAdo peakswhen compared
with the voltammogram obtained before incubation, are
explained taking into account the breaking of intrastrand
hydrogen bonds between complementary bases of the
ssDNAnucleotide chain. The application ofþ0.90 Vduring
2 minutes to the ssDNA-biosensor previously incubated in
5 mM glivec, Figure 5, full line, causes the complete oxida-
tion of glivecmolecules attached to the immobilized ssDNA
and the formation of Pglivec, peak 3a. The peak at Epa¼
þ0.45 V is again seen.
These experiments show that glivec also interacts with
single stranded polynucleotides.
3.4. In Situ Study of Glivec-Polyhomonucleotides
Interaction
In order to obtain more information about the origin of the
peak atEpa¼þ0.45 Vobserved after the oxidation of glivec
previously bounded to DNA, several experiments using a
GCE modified with polynucleotides of known sequences
were performed.
First, the GCE surface was modified as described in
Section 2.4 with a polyhomonucleotide that contains only
residues of guanine, poly[G]. A DP voltammogram ob-
tained in pH 4.5 0.1 M acetate buffer shows only a peak at
Epa¼þ1.02 V, corresponding to dGuo oxidation, Fig-
ure 6A, dashed line. When a new poly[G]-biosensor was
incubated for 2minutes in 5 mMglivec, peak 1a, correspond-
ing to the oxidation of the glivec molecules bound to the
immobilized poly[G] strands, also appeared, Figure 6A,
dotted line. When the poly[G]-biosensor previously incu-
Fig. 4. DP voltammograms obtained with the dsDNA biosensor
in pH 4.5 0.1 M acetate buffer after incubation for 2 minutes with
5 mM glivec (—) before and after application of þ0.90 V during
(- - - -) 1 and ( ··· · · · ) 2 minutes.
Fig. 5. DP voltammograms obtained with a multilayer ssDNA
biosensor in pH 4.5 0.1 M acetate buffer (- - - -) before and after
incubation for 2 minutes with 5 mM glivec ( ·· · · · · ) without and (—)
with the application of þ0.90 V during 2 minutes.
1967Voltammetric Behavior of Antileukemia Drug Glivec. Part III
Electroanalysis 18, 2006, No. 19-20, 1963 – 1970 www.electroanalysis.wiley-vch.de H 2006 WILEY-VCH Verlag GmbH&Co. KGaA, Weinheim
bated in glivec was conditioned for 2 minutes at a potential
of þ0.90 V, peak 1a disappeared due to the complete
oxidation of glivec molecules, and the occurrence of peak 3a
shows the formation of Pglivec. However, no peak at Epa¼
þ0.45 V was observed, Figure 6A, full line.
In the second series of experiments the electrode surface
was modified in the same way with poly[A], a polyhomo-
nucleotide that contains only residues of adenine. There-
fore, theDP voltammogram obtained in supporting electro-
lyte shows only the peak dAdo at Epa¼þ1.26 V, Figure 6B,
dashed line. A newly prepared poly[A]-biosensor was
incubated in a glivec solution and the DP voltammogram
obtained in buffer shows both dAdo and peak 1a, Figure 6B,
dotted line. The increase in the dAdo peak can be explained
considering the unwinding of the double-helical structure of
poly[A] in acid media [24, 29]. After interaction with glivec,
conformational changes take place in the immobilized
poly[A] leading to a higher dAdo peak. On conditioning a
previously glivec incubated poly[A]-biosensor at a potential
of þ0.90 V during 2 minutes, the glivec molecules are all
oxidized giving rise to Pglivec, peak 3a Figure 6B, full line. In
this case, the peak at Epa¼þ0.45 V occurs with a higher
current when compared with the same peak obtained at
either dsDNA or ssDNA biosensors
These experiments using poly[G] and poly[A]-biosensors,
clearly show that the peak at Epa¼þ0.45 V is directly
related with the oxidation of adenine residues on the DNA-
biosensor and its potential corresponds to the oxidation of
2,8-dihydroxyadenine (2,8-DHA) [30], the main oxidation
product of adenine.
However, when the biosensor is conditioned at þ0.90 V,
glivec is oxidized leading to formation of Pglivec, which is
electroactive and adsorbs very strongly onto the electrode
surface. At the glivec oxidation potential both the oxidation
of glivec and of the formed Pglivec occur. Hence, it is difficult
to distinguish the process that leads to the formation of
2,8-DHA. This can be overcome in the following experi-
ment which investigates the interaction between Pglivec
adsorbed at the GCE surface and poly[A].
AdsorptionofPglivec at theGCEsurfacewas undertakenas
described in Section 2.5. The GCE with adsorbed Pglivec was
then placed in a solution containing 60 mg mL1 poly[A] in
pH 4.5 0.1 M acetate buffer allowing free adsorption to
occur during 2minutes.After washingwith deionizedwater,
the GCE was transferred to the supporting electrolyte
where a potential that allows the oxidation of Pglivec
(þ0.35 V during 2 minutes) was applied. It is possible to
observe the formation of 2,8-DHA on the voltammogram
obtained, Figure 7, full line, at Epa¼þ0.45 V (see inset).
On the other hand, the oxidation of Pglivec is a reversible
process. ThePglivec adsorbedon theGCE is reducedwhen the
electrode is conditioned during 2 minutes at a potential of
þ0.20 V. A higher 2,8-DHA oxidation peak is obtained on
the DP voltammogram obtained after reducing the adsor-
bed oxidized Pglivec. Thus, it is necessary to reduce the
oxidized Pglivec in order to be able to form 2,8-DHA.
Fig. 6. DP voltammograms obtained with a multilayer A)
poly[G] and B) poly[A] biosensors in pH 4.5 0.1 M acetate buffer
(- - - -) before and after incubation for 2 minutes with 5 mM glivec
( ·· · · · · ) without and (—) with the application of þ0.90 V during 2
minutes.
Fig. 7. DP voltammograms obtained in pH 4.5 0.1 M acetate
buffer with Pglivec and poly[A] adsorbed at the GCE surface after
application of þ0.35 V during 2 minutes (—) without and ( ··· · · · )
with conditioning the electrode for 2 minutes at þ0.20 V (for
more details see Section 3.4).
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3.5. Mechanism of Glivec-DNA Oxidative Damage
The results presented give experimental evidence that glivec
molecules interact with dsDNA causing distortion of the
double helix. A schematic model for the interaction
between glivec and DNA is proposed in Scheme 2. Electro-
chemical experiments carried out at an electrode modified
with polynucleotides of known sequence lead to the
conclusion that interaction between glivec andDNA occurs
preferentially at adenine rich segments of DNA.Also, it has
been demonstrated that glivec molecules can undergo
oxidation even after binding to dsDNA.
Glivec is oxidized leading to formation of Pglivec. At the
glivec oxidation potential both the oxidation of glivec and of
the formed Pglivec occur. The oxidation of Pglivec is a reversible
process, and 2,8-DHA is detected only after reducing the
adsorbed oxidized Pglivec.
It is proposed that the electrons necessary to reduce the
oxidized Pglivec moieties are transferred from the adenine
molecules. Electron transfer from the adenine moiety in
DNA to the oxidized Pglivec gives rise to reduced Pglivec and
leads to the formation of 2,8-DHA.
2,8-DHA is themain adenine oxidation product and is the
main clinical manifestation related to the metabolic defi-
ciency of the purine salvage enzyme adenine phosphoribo-
syltransferase, which converts adenine from the nucleotide
pool into adenosine monophosphate. In patients with this
metabolic deficiency, the accumulated adenine is converted
by xanthine dehydrogenase to 8-hydroxyadenine and then
to 2,8-DHA. The precipitation and crystallization of 2,8-
DHA can lead to stone formation in various parts of the
urinary tract, leading to the loss of the kidneys.
4. Conclusions
ADNAbiosensor was successfully used for the detection of
the interaction between DNA and the antileukemia drug
glivec. TheDNAbiosensor enabled the preconcentration of
glivec onto the sensor surface. Monitoring the modification
of guanosine and adenosine oxidation peak currents, it was
concluded that glivec binds to dsDNA leading to modifica-
tions to the dsDNA structure, exposing more purinic
residues to the electrode surface and facilitating their
oxidation. Using polynucleotides of known sequences it
was shown that glivec interacts with DNA especially at
adenine enriched segments. By controlling the potential, the
in situ electrochemical generation of glivec oxidation
product inside the DNA double helix leads to the oxidation
of adenine residues, and the detection of 2,8-dihydroxyade-
nine was possible.
The approach described can be used advantageously for
the understanding of dsDNA interactions with various
complex agents and individual chemicals of environmental,
food and medical interest. The use of voltammetric techni-
ques for the in situ generation of reactive intermediates is, in
a successful way, a complementary tool for the study of
biomolecular interaction mechanisms.
Scheme 2. Proposed interaction mechanism between glivec and DNA.
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